We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

Arecor Therapeutics

AT278 ultra-concentrated insulin superior to benchmarks

Update | 20 May 2024

Arecor Therapeutics

FY23 results evidence broader revenue base

Lighthouse | 16 May 2024

ANGLE

Gathering momentum in Pharma Services

Update | 14 May 2024

HUTCHMED

Strong US Fruzaqla Q1; EU approval could come soon

Lighthouse | 13 May 2024

Arecor Therapeutics

Novel diabetes drug-device deal inked with Medtronic

Lighthouse | 09 May 2024

Avacta

Therapeutics focus sharpening; cash to key catalysts

Lighthouse | 30 April 2024

Futura Medical

Eroxon poised for launch in key US market

Outlook | 25 April 2024

Avacta

AACR data continue to support confidence in AVA6000

Lighthouse | 10 April 2024

Futura Medical

Profitability in sight as partner preps for US launch

Lighthouse | 10 April 2024

HUTCHMED

Executing consistently on the road to breakeven

Outlook | 03 April 2024
1 2 3 4 5 6 7 8 9 10 >
412 results found.